** U.S. drug developer Amneal Pharmaceuticals AMRX.O rises 4.09% to $8.15 in premarket trading
** J.P.Morgan upgrades to "overweight" from "neutral"; lifts PT from $9 to $12, ~42% upside to last close of $7.83
** Says co well-positioned for sustainable high single-digit growth, driven by strong portfolio of complex generics and biosimilars
** Expects AMRX to outperform peers significantly on successful launch of Crexont, used to treat Parkinson's disease, and AvKARE's (co's independent subsidiary) impressive growth
** Stock rated "buy" on avg; median PT is $11 - LSEG
** AMRX down 1.13% so far this year, as of Friday's close
(Reporting by Rashika Singh in Bengaluru)
((rashika.singh@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.